Home > Publications database > All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply. > print

001     282460
005     20240229155041.0
024 7 _ |a 10.1016/S2352-3026(23)00242-9
|2 doi
024 7 _ |a pmid:37652598
|2 pmid
024 7 _ |a 2352-3026
|2 ISSN
024 7 _ |a 2451-9960
|2 ISSN
037 _ _ |a DKFZ-2023-01775
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Döhner, Hartmut
|b 0
245 _ _ |a All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results - Authors' reply.
260 _ _ |a London [u.a.]
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1693827086_11016
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Correspondence
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 1
|u dkfz
700 1 _ |a Ganser, Arnold
|b 2
773 _ _ |a 10.1016/S2352-3026(23)00242-9
|g Vol. 10, no. 9, p. e707 -
|0 PERI:(DE-600)2802056-X
|n 9
|p e707
|t The lancet / Haematology
|v 10
|y 2023
|x 2352-3026
909 C O |p VDB
|o oai:inrepo02.dkfz.de:282460
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET HAEMATOL : 2022
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b LANCET HAEMATOL : 2022
|d 2023-08-26
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21